Colchicine for ischemia with no obstructive coronary artery disease and microvascular dysfunction

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507981-17-00

Acronym

2023-507981-17-00

Enrollment

100

Registered

2023-12-19

Start date

2024-11-20

Completion date

Unknown

Last updated

2025-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CMD

Brief summary

Change in myocardial bloodflow reserve assessed by [15O]H2O-PET-scan from baseline and after 6 months

Detailed description

Change in Symptom burden assessed by Seattle Angina Questionnaire at baseline and 6 months, Identifying certain protein pathways and functional mechanisms in arteries associated with colchicine treatment., Changes in vascular function and protein pathway analyses in subsamples, Change in MBF assessed by [15O]H2O-PET-scan from baseline and after 6 months, Change in hMBF assessed by [15O]H2O-PET-scan from baseline and after 6 months

Interventions

DRUGColchicine 500 microgram Tablets

DRUGADENOSINE

DRUGREGADENOSON

DRUGPLACEBO

DRUG-

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change in myocardial bloodflow reserve assessed by [15O]H2O-PET-scan from baseline and after 6 months	—

Secondary

Measure	Time frame
Change in Symptom burden assessed by Seattle Angina Questionnaire at baseline and 6 months, Identifying certain protein pathways and functional mechanisms in arteries associated with colchicine treatment., Changes in vascular function and protein pathway analyses in subsamples, Change in MBF assessed by [15O]H2O-PET-scan from baseline and after 6 months, Change in hMBF assessed by [15O]H2O-PET-scan from baseline and after 6 months	—

Measure

Time frame

—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026